@myESMO @LungCancerRx @OncoAlert @oncodaily 8/ Full cards in the graphic. What's on your #ESMO26 lung list that I missed? #LCSM @LungCancerRx @OncoAlert @oncodaily

@myESMO @LungCancerRx @OncoAlert @oncodaily 7/ Early-phase ADCs: ABBV-706 (3837RO, Oct 26, 10:15 CET), SEZ6 ADC in relapsed SCLC. Where does it fit next to DLL3 and B7-H3? Temab-A (2658RO, Oct 24, 09:27 CEST), c-Met ADC, phase 1 OS in NSQ NSCLC. Does c-Met level select who benefits? @LungCancerRx @OncoAlert @oncodaily

@myESMO @LungCancerRx @OncoAlert @oncodaily 6/ PANKU-Lung01 (LBA71), Oct 26, 09:14 CET Iza-bren (EGFR×HER3 bispecific ADC) vs platinum–pemetrexed after 3rd-gen EGFR TKI. Interim PFS met per Sichuan Biokin. First effect sizes: how big, and at what toxicity? @LungCancerRx @OncoAlert @oncodaily

@myESMO @LungCancerRx @OncoAlert @oncodaily 5/ OptiTROP-Lung06 (LBA66), Oct 25, 10:53 CET Sac-TMT + pembro vs chemo + pembro, 1L PD-L1-negative nonsquamous NSCLC. PFS met per Kelun-Biotech. Can a TROP2 ADC replace the platinum doublet alongside IO? @LungCancerRx @OncoAlert @oncodaily

@myESMO @LungCancerRx @OncoAlert @oncodaily 4/ Krascendo 1 (LBA5), Oct 25, 16:30 CET Divarasib vs sotorasib or adagrasib, pretreated KRAS G12C NSCLC. Roche reports PFS + OS wins. How wide is the gap within the G12C class, and at what tolerability? @LungCancerRx @OncoAlert @oncodaily

@myESMO @LungCancerRx @OncoAlert @oncodaily 3/ DeLLphi-305 (LBA3), Oct 24, 17:18 CEST Tarlatamab + durvalumab as 1L maintenance in ES-SCLC. Amgen reports an OS win at interim. How large, and can clinics deliver T-cell engager monitoring in maintenance? @LungCancerRx @OncoAlert @oncodaily

@myESMO @LungCancerRx @OncoAlert @oncodaily 2/ SAFFRON (LBA6), Oct 25, 16:54 CET Osimertinib + savolitinib vs platinum–pemetrexed, EGFRm MET-high NSCLC after osimertinib. Sponsors report PFS + OS wins. How big, and which MET IHC/FISH cutoff selects patients? @LungCancerRx @OncoAlert @oncodaily